<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03580902</url>
  </required_header>
  <id_info>
    <org_study_id>41941</org_study_id>
    <nct_id>NCT03580902</nct_id>
  </id_info>
  <brief_title>CBT4CBT for Office Based Buprenorphine</brief_title>
  <official_title>A Method to Increase Buprenorphine Treatment Capacity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CBT4CBT, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CBT4CBT, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this Phase II SBIR/STTR project, our Specific Aim will be to determine if the use of
      CBT4CBT-Buprenorphine leads to clinically significant improved outcomes and increased
      retention for buprenorphine maintenance patients in a larger and diverse population of
      individuals seeking buprenorphine treatment in primary care (N=100).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this phase, 100 individuals entering buprenorphine maintenance at the primary care clinic
      (Central Medical Unit, CMU) will be randomized to either (1) standard buprenorphine
      maintenance in which counseling is offered on site, or (2) standard buprenorphine maintenance
      with CBT4CBT-Buprenorphine substituting for on-site counseling. This will be a 12-week trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of urine toxicology screens that are negative for opioids by group.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent of urine toxicology screens, collected weekly, that are negative for opioid metabolites.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Opioid-use Disorder</condition>
  <arm_group>
    <arm_group_label>Standard Buprenorphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants assigned to this arm will received buprenorphine treatment consistent with standard practice at the study site. This includes induction by a physician, regular meetings with a physician for medical management, urine monitoring, and prescription of buprenorphine, with access to behavioral support services.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Buprenorphine plus CBT4CBT-Buprenorphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this condition will receive Standard Buprenorphine as described above, with the addition of access to the CBT4CBT-Buprenorphine program, which is a web-based program that covers basic knowledge about buprenorphine treatment as well as teaches cognitive and behavioral coping skills.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CBT4CBT-Buprenorphine</intervention_name>
    <description>Computerized, user-driven cognitive-behavioral therapy (CBT) web-based program adapted for use in office based buprenorphine treatment</description>
    <arm_group_label>Standard Buprenorphine plus CBT4CBT-Buprenorphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine/naloxone</intervention_name>
    <description>Standard outpatient buprenorphine maintenance</description>
    <arm_group_label>Standard Buprenorphine</arm_group_label>
    <arm_group_label>Standard Buprenorphine plus CBT4CBT-Buprenorphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets current Diagnostic Statistical Manual (DSM-5) criteria for opioid use disorder

          -  Requesting buprenorphine maintenance treatment at Central Medical Unit of the APT
             Foundation

        Exclusion Criteria:

          -  Unstabilized psychotic disorder

          -  Currently suicidal or homicidal

          -  Current cocaine, benzodiazepine, or alcohol use disorder.

          -  Any history of PCP (phencyclidine) use.

          -  Pregnant or lactating

          -  Any other physical or mental condition that would contraindicate office-based
             buprenorphine maintenance treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia Shi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APT Foundation, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Dwy</last_name>
    <phone>203 285 1754</phone>
    <email>sdwy@aptfoundation.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Skye Orazietti</last_name>
    <phone>203 285 1754</phone>
    <email>sorazietti@aptfoundation.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Central Medical Unit of the APT Foundation</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511-5991</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Dwy</last_name>
      <phone>203-285-1754</phone>
      <email>sdwy@aptfoundation.org</email>
    </contact>
    <contact_backup>
      <last_name>Skye Orazietti</last_name>
      <phone>203.285.1754</phone>
      <email>sorazietti@aptfoundation.org</email>
    </contact_backup>
    <investigator>
      <last_name>Julia Shi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 25, 2018</study_first_submitted>
  <study_first_submitted_qc>July 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2018</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

